Pregnancy prognosis in women with anti-Müllerian hormone below the tenth percentile

References

• Chambers GM, Sullivan EA, Ishihara O, et al. The economic impact of assisted reproductive technology: a review of selected developed countries. Fertil Steril 2009;91:2281–94
   PubMed Web of Science ®Google Scholar
• Devlin N, Parkin D. Funding fertility: issues in the allocation and distribution of resources to assisted reproduction technologies. Hum Fertil (Camb) 2003;6:S2–6
   Google Scholar
• Maheshwari A, Hamilton M, Bhattacharya S. A survey of clinicians’ views on age and access to IVF and the use of tests of ovarian reserve prior to IVF in the United Kingdom. Hum Fertil (Camb) 2008;11:23–7
   PubMedGoogle Scholar
• Kamble L, Gudi A, Shah A, Homburg R. Poor responders to controlled ovarian hyperstimulation for in vitro fertilisation (IVF). Hum Fertil (Camb) 2011;14:230–45
   PubMed Web of Science ®Google Scholar
• Broekmans FJ, Kwee J, Hendriks DJ, et al. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 2006;12:685–718
   PubMed Web of Science ®Google Scholar
• Broer SL, Mol B, Dólleman M, et al. The role of anti-Müllerian hormone assessment in assisted reproductive technology outcome. Curr Opin Obstet Gynecol 2010;22:193–201
   PubMed Web of Science ®Google Scholar
• Jayaprakasan K, Campbell B, Hopkisson J, et al. A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertil Steril 2010;93:855–64
   PubMed Web of Science ®Google Scholar
• Scheffer GJ, Broekmans FJ, Bancsi LF, et al. Quantitative transvaginal two- and three-dimensional sonography of the ovaries: reproducibility of antral follicle counts. Ultrasound Obstet Gynecol 2002;20:270–5
   PubMed Web of Science ®Google Scholar
• Lujan ME, Chizen DR, Peppin AK, et al. Assessment of ultrasonographic features of polycystic ovaries is associated with modest levels of inter-observer agreement. J Ovarian Res 2009;2:6
   PubMed Web of Science ®Google Scholar
• van Disseldorp J, Lambalk CB, Kwee J, et al. Comparison of inter and intracycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod 2010;25:221–7
   PubMed Web of Science ®Google Scholar
• Weenen C, Laven JS, Von Bergh AR, et al. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004;10:77–83
   PubMed Web of Science ®Google Scholar
• Lee MM, Donahoe PK, Hasegawa T, et al. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab 1996;81:571–6
   PubMed Web of Science ®Google Scholar
• Ebner T, Sommergruber M, Moser M, et al. Basal level of anti-Mullerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod 2006;21:2022–6
   PubMed Web of Science ®Google Scholar
• Silberstein T, MacLaughlin DT, Shai I, et al. Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. Hum Reprod 2006;21:159–63
   PubMed Web of Science ®Google Scholar
• La Marca A, Sighinolfi G, Radi D, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010;16:113–30
   PubMed Web of Science ®Google Scholar
• Lekamge DN, Barry M, Kolo M, et al. Anti-Mullerian hormone as a predictor of IVF outcome. Reprod Biomed Online 2007;14:602–10
   PubMed Web of Science ®Google Scholar
• Nelson SM, Yates RW, Fleming R. Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles–implications for individualization of therapy. Hum Reprod 2007;22:2414–21
   PubMed Web of Science ®Google Scholar
• Lee TH, Liu CH, Huang CC, et al. Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles. Reprod Biol Endocrinol 2009;7:100
   PubMed Web of Science ®Google Scholar
• La Marca A, Nelson SM, Sighinolfi G, et al. Anti-Müllerian hormone-based prediction model for a live birth in assisted reproduction. Reprod Biomed Online 2011;22:341–9
   PubMed Web of Science ®Google Scholar
• Smeenk JM, Sweep FC, Zielhuis GA, et al. Antimullerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection. Fertil Steril 2007;87:223–6
   PubMed Web of Science ®Google Scholar
• Tocci A, Ferrero S, Iacobelli M, Greco E. Negligible serum anti-mullerian hormone: pregnancy and birth after a 1-month course of an oral contraceptive, ovarian hyperstimulation, and intracytoplasmic sperm injection. Fertil Steril 2009;92:395.e9–395.e12
   Web of Science ®Google Scholar
• Weghofer A, Dietrich W, Barad DH, Gleicher N. Live birth chances in women with extremely low-serum anti-Mullerian hormone levels. Hum Reprod 2011;26:1905–9
   PubMed Web of Science ®Google Scholar
• Fraisse T, Ibecheole V, Streuli I, et al. Undetectable serum anti-Mullerian hormone levels and occurrence of ongoing pregnancy. Fertil Steril 2008;89:723.e9–11
   Web of Science ®Google Scholar
• Gleicher N, Weghofer A, Barad DH. Anti-Mullerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve. Fertil Steril 2010;94:2824–7
   PubMed Web of Science ®Google Scholar
• Wang JG, Douglas NC, Nakhuda GS, et al. The association between anti-Müllerian hormone and IVF pregnancy outcomes is influenced by age. Reprod Biomed Online 2010;21:757–61
   PubMed Web of Science ®Google Scholar
• Wallace AM, Faye SA, Fleming R, Nelson SM. A multicentre evaluation of the new Beckman Coulter anti-Mullerian hormone immunoassay (AMH Gen II). Ann Clin Biochem 2011;48:370–3
   PubMed Web of Science ®Google Scholar
• Gardner DK, Schoolcraft WB. In vitro culture of human blastocyst. In: Jansen R and Mortimer D, eds. Towards reproductive certainty: infertility and genetics beyond 1999. Carnforth, UK: Parthenon Press; 1999: 378–88
   Google Scholar
• Gardner DK, Schoolcraft WB. Culture and transfer of human blastocysts. Curr Opin Obstet Gynecol 1999;11:307–11
   PubMed Web of Science ®Google Scholar
• Nelson SM, Yates RW, Lyall H, et al. Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 2009;24:867–75
   PubMed Web of Science ®Google Scholar
• Lee RK, Wu FS, Lin MH, et al. The predictability of serum anti-Müllerian level in IVF/ICSI outcomes for patients of advanced reproductive age. Reprod Biol Endocrinol 2011;9:115
   PubMed Web of Science ®Google Scholar